Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 19/20 | 0.80 |
| ▸ | KCNH2 | Q12809 | 12/20 | 0.80 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4485462 | 0.93 | HRH3 (0.80) | HRH3KCNH2ADRA1A | |
| SCHEMBL2662552 | 0.93 | HRH3 (0.74) | HRH3KCNH2ADRA1A | |
| SCHEMBL4485049 | 0.89 | HRH3 (1.00) | HRH3KCNH2ADRA1A | |
| SCHEMBL4474009 | 0.89 | HRH3 (1.00) | HRH3KCNH2ADRA1A | |
| SCHEMBL4486506 | 0.89 | HRH3 (1.00) | HRH3KCNH2ADRA1A | |
| SCHEMBL4470400 | 0.89 | HRH3 (1.00) | HRH3KCNH2ADRA1A | |
| SCHEMBL4466090 | 0.88 | HRH3 (0.98) | HRH3KCNH2ADRA1A | |
| SCHEMBL4475973 | 0.87 | HRH3 (0.73) | HRH3KCNH2ADRA1A | |
| SCHEMBL3808868 | 0.87 | HRH3 (0.68) | HRH3KCNH2ADRA1A | |
| SCHEMBL4476652 | 0.86 | HRH3 (0.79) | HRH3KCNH2ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 191 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1717230-B1 | FUSED-RING 4-OXOPYRIMIDINE DERIVATIVE | MSD KK (JP) | 2014-08-06 | — | — | EP | claimed |
| EP-1717230-A1 | FUSED-RING 4-OXOPYRIMIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-02 | — | — | EP | claimed |
| US-20050182045-A1 | Fused ring 4-oxopyrimidine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-08-18 | — | — | US | claimed |
| EP-3243385-B1 | NOVEL CYCLIC AZABENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME (US) | 2021-01-13 | — | — | EP | disclosed |
| EP-3055288-B1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2020-12-16 | — | — | EP | disclosed |
| EP-2880028-B1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2020-09-30 | — | — | EP | disclosed |
| EP-2888007-B1 | BENZIMIDAZOLE TETRAHYDROFURAN DERIVATIVES USEFUL AS AMP-ACTIVATED PROTEIN KINASE ACTIVATORS | MERCK SHARP & DOHME (US) | 2019-09-18 | — | — | EP | disclosed |
| EP-2887807-B1 | BENZIMIDAZOLE HEXAHYDROFURO[3,2-B]FURAN DERIVATIVES USEFUL AS AMP-ACTIVATED PROTEIN KINASE ACTIVATORS | MERCK SHARP & DOHME (US) | 2019-09-18 | — | — | EP | disclosed |
| EP-3068768-B1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2019-07-31 | — | — | EP | disclosed |
| EP-2888006-B1 | NOVEL AZABENZIMIDAZOLE TETRAHYDROPYRAN DERIVATIVES USEFUL AS AMPK ACTIVATORS | MERCK SHARP & DOHME (US) | 2019-04-24 | — | — | EP | disclosed |
| EP-2888005-B1 | NOVEL AZABENZIMIDAZOLE HEXAHYDROFURO[3,2-B]FURAN DERIVATIVES | MERCK SHARP & DOHME (US) | 2019-04-03 | — | — | EP | disclosed |
| WO-2008039327-A2 | METHOD OF TREATMENT USING FATTY ACID SYNTHESIS INHIBITORS | MERCK & CO., INC. (US) | 2008-04-03 | — | — | WO | disclosed |
| WO-2008024284-A2 | SULFONYLATED PIPERAZINES AS CANNABINOID-1 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2008-02-28 | — | — | WO | disclosed |
| WO-2007136571-A1 | PRO-DRUGS OF TERTIARY ALCOHOLS | MERCK & CO., INC. (US) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007120655-A2 | SUBSTITUTED IMIDAZOLE 4-CARBOXAMIDES AS CHOLECYSTOKININ-1 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007120718-A2 | SUBSTITUTED IMIDAZOLE 4-CARBOXAMIDES AS CHOLECYSTOKININ-1 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-10-25 | — | — | WO | disclosed |
| US-20070244048-A1 | Neuromedin U receptor agonists and uses thereof | MERCK SHARP & DOHME CORP. | 2007-10-18 | — | — | US | disclosed |
| WO-2007064566-A2 | HETEROCYCLE-SUBSTITUTED 3-ALKYL AZETIDINE DERIVATIVES | MERCK & CO., INC. (US) | 2007-06-07 | — | — | WO | disclosed |
| EP-1717230-A1 | FUSED-RING 4-OXOPYRIMIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-02 | — | — | EP | disclosed |
| US-20050182045-A1 | Fused ring 4-oxopyrimidine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182045-A1 | Fused ring 4-oxopyrimidine derivative | HRH4, HRH2, HRH3 | HRH3 3/4885KCNH2 299/4885ADRA1A 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.